Teicoplanin metabolism in humans

A. Bernareggi, A. Borghi, M. Borgonovi, L. Cavenaghi, P. Ferrari, K. Vékey, M. Zanol, L. F. Zerilli

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Teicoplanin, a lipoglycopeptide antibiotic, consists of five major components (A2-1 through A2-5), one hydrolysis component (A3-1), and four minor components (RS-1 through RS-4). All the major components contain an N- acyl-β-D-glucosamine, but they differ in the lengths and branchings of their acyl-aliphatic chains. Previous studies with radiolabeled teicoplanin in rats and humans have shown that the drug is eliminated by the renal route and that metabolic transformation is very minor, about 5%. A possible metabolic transformation of teicoplanin into A3-1 was also suggested. In the present study in humans, two metabolites (metabolites 1 and 2; 2 to 3% of total teicoplanin) were isolated after intravenous administration of radiolabeled teicoplanin. After purification, their structures were determined by fast atom bombardment mass spectroscopy and 1H nuclear magnetic resonance spectroscopy on the basis of the well-known correlations established in this field, and they were found to be new teicoplaninlike molecules, bearing 8- hydroxydecanoic and 9-hydroxydecanoic acyl moieties. This metabolic transformation is likely due to hydroxylation in the Ω-2 and Ω-1 positions for metabolites 1 and 2, respectively, of the C-10 linear side chain of component A2-3. This might explain the low extent of metabolism of teicoplanin if we consider that only component A2-3 has a linear chain that is susceptible to such oxidation.

Original languageEnglish
Pages (from-to)1744-1749
Number of pages6
JournalAntimicrobial Agents and Chemotherapy
Volume36
Issue number8
Publication statusPublished - 1992

Fingerprint

Teicoplanin
varespladib methyl
Fast Atom Bombardment Mass Spectrometry
Glucosamine
Hydroxylation
Intravenous Administration
Hydrolysis
Magnetic Resonance Spectroscopy
Anti-Bacterial Agents
Kidney
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Bernareggi, A., Borghi, A., Borgonovi, M., Cavenaghi, L., Ferrari, P., Vékey, K., ... Zerilli, L. F. (1992). Teicoplanin metabolism in humans. Antimicrobial Agents and Chemotherapy, 36(8), 1744-1749.

Teicoplanin metabolism in humans. / Bernareggi, A.; Borghi, A.; Borgonovi, M.; Cavenaghi, L.; Ferrari, P.; Vékey, K.; Zanol, M.; Zerilli, L. F.

In: Antimicrobial Agents and Chemotherapy, Vol. 36, No. 8, 1992, p. 1744-1749.

Research output: Contribution to journalArticle

Bernareggi, A, Borghi, A, Borgonovi, M, Cavenaghi, L, Ferrari, P, Vékey, K, Zanol, M & Zerilli, LF 1992, 'Teicoplanin metabolism in humans', Antimicrobial Agents and Chemotherapy, vol. 36, no. 8, pp. 1744-1749.
Bernareggi A, Borghi A, Borgonovi M, Cavenaghi L, Ferrari P, Vékey K et al. Teicoplanin metabolism in humans. Antimicrobial Agents and Chemotherapy. 1992;36(8):1744-1749.
Bernareggi, A. ; Borghi, A. ; Borgonovi, M. ; Cavenaghi, L. ; Ferrari, P. ; Vékey, K. ; Zanol, M. ; Zerilli, L. F. / Teicoplanin metabolism in humans. In: Antimicrobial Agents and Chemotherapy. 1992 ; Vol. 36, No. 8. pp. 1744-1749.
@article{9543b51fe6b64d6db2be0947186d6d80,
title = "Teicoplanin metabolism in humans",
abstract = "Teicoplanin, a lipoglycopeptide antibiotic, consists of five major components (A2-1 through A2-5), one hydrolysis component (A3-1), and four minor components (RS-1 through RS-4). All the major components contain an N- acyl-β-D-glucosamine, but they differ in the lengths and branchings of their acyl-aliphatic chains. Previous studies with radiolabeled teicoplanin in rats and humans have shown that the drug is eliminated by the renal route and that metabolic transformation is very minor, about 5{\%}. A possible metabolic transformation of teicoplanin into A3-1 was also suggested. In the present study in humans, two metabolites (metabolites 1 and 2; 2 to 3{\%} of total teicoplanin) were isolated after intravenous administration of radiolabeled teicoplanin. After purification, their structures were determined by fast atom bombardment mass spectroscopy and 1H nuclear magnetic resonance spectroscopy on the basis of the well-known correlations established in this field, and they were found to be new teicoplaninlike molecules, bearing 8- hydroxydecanoic and 9-hydroxydecanoic acyl moieties. This metabolic transformation is likely due to hydroxylation in the Ω-2 and Ω-1 positions for metabolites 1 and 2, respectively, of the C-10 linear side chain of component A2-3. This might explain the low extent of metabolism of teicoplanin if we consider that only component A2-3 has a linear chain that is susceptible to such oxidation.",
author = "A. Bernareggi and A. Borghi and M. Borgonovi and L. Cavenaghi and P. Ferrari and K. V{\'e}key and M. Zanol and Zerilli, {L. F.}",
year = "1992",
language = "English",
volume = "36",
pages = "1744--1749",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "8",

}

TY - JOUR

T1 - Teicoplanin metabolism in humans

AU - Bernareggi, A.

AU - Borghi, A.

AU - Borgonovi, M.

AU - Cavenaghi, L.

AU - Ferrari, P.

AU - Vékey, K.

AU - Zanol, M.

AU - Zerilli, L. F.

PY - 1992

Y1 - 1992

N2 - Teicoplanin, a lipoglycopeptide antibiotic, consists of five major components (A2-1 through A2-5), one hydrolysis component (A3-1), and four minor components (RS-1 through RS-4). All the major components contain an N- acyl-β-D-glucosamine, but they differ in the lengths and branchings of their acyl-aliphatic chains. Previous studies with radiolabeled teicoplanin in rats and humans have shown that the drug is eliminated by the renal route and that metabolic transformation is very minor, about 5%. A possible metabolic transformation of teicoplanin into A3-1 was also suggested. In the present study in humans, two metabolites (metabolites 1 and 2; 2 to 3% of total teicoplanin) were isolated after intravenous administration of radiolabeled teicoplanin. After purification, their structures were determined by fast atom bombardment mass spectroscopy and 1H nuclear magnetic resonance spectroscopy on the basis of the well-known correlations established in this field, and they were found to be new teicoplaninlike molecules, bearing 8- hydroxydecanoic and 9-hydroxydecanoic acyl moieties. This metabolic transformation is likely due to hydroxylation in the Ω-2 and Ω-1 positions for metabolites 1 and 2, respectively, of the C-10 linear side chain of component A2-3. This might explain the low extent of metabolism of teicoplanin if we consider that only component A2-3 has a linear chain that is susceptible to such oxidation.

AB - Teicoplanin, a lipoglycopeptide antibiotic, consists of five major components (A2-1 through A2-5), one hydrolysis component (A3-1), and four minor components (RS-1 through RS-4). All the major components contain an N- acyl-β-D-glucosamine, but they differ in the lengths and branchings of their acyl-aliphatic chains. Previous studies with radiolabeled teicoplanin in rats and humans have shown that the drug is eliminated by the renal route and that metabolic transformation is very minor, about 5%. A possible metabolic transformation of teicoplanin into A3-1 was also suggested. In the present study in humans, two metabolites (metabolites 1 and 2; 2 to 3% of total teicoplanin) were isolated after intravenous administration of radiolabeled teicoplanin. After purification, their structures were determined by fast atom bombardment mass spectroscopy and 1H nuclear magnetic resonance spectroscopy on the basis of the well-known correlations established in this field, and they were found to be new teicoplaninlike molecules, bearing 8- hydroxydecanoic and 9-hydroxydecanoic acyl moieties. This metabolic transformation is likely due to hydroxylation in the Ω-2 and Ω-1 positions for metabolites 1 and 2, respectively, of the C-10 linear side chain of component A2-3. This might explain the low extent of metabolism of teicoplanin if we consider that only component A2-3 has a linear chain that is susceptible to such oxidation.

UR - http://www.scopus.com/inward/record.url?scp=0026635444&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026635444&partnerID=8YFLogxK

M3 - Article

VL - 36

SP - 1744

EP - 1749

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 8

ER -